Paradigm Medical Communications, LLC

multiple award-winning medical education company that develops innovative medical education activities.

[Paradigm Medical Communications, LLC @ParadigmMedCom]

LAST CHANCE! This webinar will present new guideline recommendations for the treatment of LN along with recently published data from the phase 3 REGENCY trial of the novel B-cell–depleting agent obinutuzumab in LN. Scan QR code or visit link in bio!
https://t.co/kxYHepP9DS

[Paradigm Medical Communications, LLC @ParadigmMedCom]

NEW Complimentary CME! Explore cutting-edge data on tyrosine kinase inhibitors (TKIs) delivered straight from the podium of the ARVO 2026 Annual Meeting. Don’t miss this opportunity to learn how TKIs may reshape the care of patients with neovascular AMD.
https://t.co/NSBmQkbMC4

[Paradigm Medical Communications, LLC @ParadigmMedCom]

FEATURED FREE CME WEBINAR! Molluscum Contagiosum - To Treat or Not to Treat. Link in bio or Scan QR code https://t.co/ahAvGvHdbY

[Paradigm Medical Communications, LLC @ParadigmMedCom]

LAST CHANCE! Join Benjamin J. Kim, MD and Avni Patel Finn, MD, MBA for a discussion of how to personalize care of your patients with wet age-related macular degeneration (AMD) using anti-vascular endothelial growth factor (VEGF) therapies. https://t.co/iuekZG1KwZ

[Paradigm Medical Communications, LLC @ParadigmMedCom]

COMPLIMENTARY CME - VIEW NOW! Two goals in treatment of neovascular age-related macular degeneration (nAMD) compete. Resolution of macular fluid competes with reducing treatment burden...
https://t.co/5c1fZjdwc9

[Paradigm Medical Communications, LLC @ParadigmMedCom]

FEATURED CME! Dive into detailed patient cases to understand the complexities and nuances in treatment strategies for patients with HER2 overexpression in NSCLC in this engaging virtual activity. Scan QR code to view or visit Link in bio!https://t.co/Vvml98qcg0

[Paradigm Medical Communications, LLC @ParadigmMedCom]

View Now! Join this webinar to gain insights into best practices for switching and sequencing anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD). https://t.co/WsbOwn2XvA

[Paradigm Medical Communications, LLC @ParadigmMedCom]

Complimentary CME! View Now! Join our expert faculty as they discuss how IDH and FLT3 mutations shape AML prognosis and treatment. Hear expert insights on targeted therapies, sequencing, resistance, ...https://t.co/SkB4ZKGqLb

[Paradigm Medical Communications, LLC @ParadigmMedCom]

REGISTER NOW! This complimentary CE expert-led dinner meeting will prepare optometrists for advances in nonproliferative diabetic retinopathy care that call for immediate practice shifts.
Link in Bio or Scan QR code
https://t.co/ot1h8M1PzP

[Paradigm Medical Communications, LLC @ParadigmMedCom]

NEW CME! VIEW NOW! Join this webinar to gain insights into best practices for switching and sequencing anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD)...https://t.co/auf7CrX6OC

[Paradigm Medical Communications, LLC @ParadigmMedCom]

LAST CHANCE!!! VIEW NOW! Expert guidance for PAs and NPs on food allergy, including definitions, referrals, and potential treatment options beyond allergen avoidance. Link in Bio or Scan QR code
https://t.co/qRj4w7fDbM

[Paradigm Medical Communications, LLC @ParadigmMedCom]

FEATURED FREE CME! View now! As late-phase trials of anti-TL1A therapies for IBD progress, clinicians need to stay informed on this novel mechanism of action and its potential role in personalized treatment strategies....https://t.co/oE4GahRwVQ

[Paradigm Medical Communications, LLC @ParadigmMedCom]

FEATURED CME! Explore interactive, game-based modules on obesity science, patient assessment, GLP-1 therapies, and communication strategies—all in one engaging CME program. Start learning now! Link in Bio or Scan QR code https://t.co/13Lwm3uVPn

[Paradigm Medical Communications, LLC @ParadigmMedCom]

NEW Complimentary CME! Explore key updates from ASCO/CAP guidelines and the 2025 CAP Cancer Protocol for breast cancer, focusing on HER2-low and HER2-ultralow classifications. Visit Link in bio or Scan QR code https://t.co/Uc4mhedVUk

[Paradigm Medical Communications, LLC @ParadigmMedCom]

FREE CME! Navigate the intricacies of treating patients with HER2 overexpression in NSCLC by joining this engaging virtual case-based activity. Link in bio or Scan QR code https://t.co/IkNxk8x1jC

[Paradigm Medical Communications, LLC @ParadigmMedCom]

FEATURED CME! This dynamic program explores the barriers and biases influencing LAI utilization in schizophrenia through interactive cases. A data-rich dive empowers clinicians with the knowledge to confidently integrate them into care plans. https://t.co/SW1kDz4a5S

[Paradigm Medical Communications, LLC @ParadigmMedCom]

NEW Complimentary CME! The treatment landscape of glaucoma continues to evolve, offering patients and treating ophthalmologists more options... https://t.co/Dw478XOLD9

[Paradigm Medical Communications, LLC @ParadigmMedCom]

LAST CHANCE! View Now! Join this engaging activity on TROP2-targeted ADCs in breast cancer, where faculty experts offer insights into available and emerging ADCs, present patient case studies, and share therapeutic strategies,..https://t.co/AnW2aAqnL6

[Paradigm Medical Communications, LLC @ParadigmMedCom]

“FEATURED FREE CME”! View now! An educational infographic program on pathways to care in CSU. Link in bio or Scan QR code https://t.co/7ZjUTnX0ie

[Paradigm Medical Communications, LLC @ParadigmMedCom]

NEW Complimentary CME! Click here to view the expert discussion on the role of B-cells in pMN and how emerging B-cell–targeted treatments may be incorporated into treatment. View Now! Link in Bio or Scan QR code
https://t.co/HUIDGyXin2